Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary mediastinal large B-cell lymphoma.

Maurizio Martelli1, Andrés J M Ferreri, Peter Johnson

  • 1Department of Cellular Biotecnologies and Hematology, Division of Hematology, University La Sapienza, Rome, Italy.

Critical Reviews in Oncology/Hematology
|September 9, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

The Lancet. Haematology·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

CD56<sup>+</sup>/CD38<sup>+</sup> Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the Immune Microenvironment: Engineering IL-2 Variants to Overcome Clinical Bottlenecks in PD-1 Inhibitor plus Chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant Immunotherapy in Melanoma: From Pathologic Response to Response-Adapted Management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
Same journal

Alternative splicing in breast cancer drug resistance: Mechanisms, therapeutic targeting, and clinical translation.

Critical reviews in oncology/hematology·2026
See all related articles

Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct lymphoma subtype in young women, often presenting as a mediastinal mass. Current treatments offer a 5-year survival of 65%, with prognosis influenced by disease bulk and patient factors.

Area of Science:

  • Oncology
  • Hematology
  • Pathology

Background:

  • Primary mediastinal large B-cell lymphoma (PMLBCL) is a unique B-cell lymphoma subtype.
  • It accounts for 6-10% of diffuse large B-cell lymphomas (DLBCL) and predominantly affects young females.
  • PMLBCL is characterized by a mediastinal mass and specific molecular features.

Purpose of the Study:

  • To summarize the key characteristics, molecular features, and clinical presentation of PMLBCL.
  • To review current treatment strategies and prognostic factors for PMLBCL.
  • To highlight the differences and similarities between PMLBCL and other lymphoma types.

Main Methods:

  • Review of existing literature on PMLBCL.
  • Analysis of molecular characteristics including gene mutations and expression profiles.

Related Experiment Videos

  • Evaluation of clinical presentation, staging, and treatment outcomes.

    • Main Results:

    • PMLBCL presents as an invasive anterior mediastinal mass, often causing respiratory symptoms and superior vena cava syndrome.
    • Key molecular features include 9p gains, p53 mutations, BCL-2 and MAL gene overexpression, and similarities to classic Hodgkin lymphoma gene expression.
    • CHOP regimen with radiation therapy yields a 5-year survival of 65%, with improved outcomes reported for newer regimens.

    Conclusions:

    • PMLBCL is a distinct lymphoma entity with unique clinical and molecular features.
    • Prognosis is influenced by performance status, disease bulk, LDH levels, and treatment intensity.
    • Further research into novel therapeutic approaches may improve outcomes for PMLBCL patients.